Reversal of Integrase Inhibitor- and Tenofovir Alafenamide-Related Weight Gain after Switching Back to Tenofovir DF/Emtricitabine/Efavirenz
Keyword(s):
Abstract We report a case of substantial weight gain in a virologically suppressed patient with HIV after changing his antiretroviral therapy from efavirenz/emtricitabine/tenofovir DF to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide with subsequent rapid weight loss upon switching back. The role of antiretrovirals in weight gain and loss and patient- and HIV-specific factors are discussed.
Keyword(s):
2000 ◽
Vol 18
(2)
◽
Keyword(s):
2017 ◽
Vol 27
(2)
◽
pp. 122-129
◽
Keyword(s):
Keyword(s):
2021 ◽
Vol 8
(Supplement_1)
◽
pp. S532-S533